Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with either high-risk MGUS (an early blood condition where abnormal proteins are found) or a lower-risk form of smoldering multiple myeloma (a pre-cancer condition with no symptoms yet), as defined by the trial guidelines
- You are generally able to carry out daily activities with no or minimal limitations (confirm with trial site for exact definition)
- Your blood counts and liver function are within an acceptable range, as set out by the trial guidelines (confirm with trial site for exact values)
- Your kidneys are working at a sufficient level, measured by a standard kidney function test
Who may not be able to join:
- You have been diagnosed with a higher-risk form of smoldering multiple myeloma, as defined by the trial guidelines
- You are showing signs that your condition has progressed toward active multiple myeloma, as described in the trial guidelines (confirm with trial site)
- You have been diagnosed with certain related blood or bone marrow conditions, including light-chain amyloidosis, Waldenström macroglobulinemia, solitary plasmacytoma, or active (symptomatic) multiple myeloma
- You have had a serious heart or blood vessel problem within the 3 months before joining the trial (confirm with trial site for exact details)
- You have had an infection serious enough to require a hospital stay or treatment through an IV drip within 28 days before starting the trial medication
- You have HIV, Hepatitis B, or Hepatitis C that is not well controlled, or any other ongoing or unexplained infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Phone: 844-734-6643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of Adverse Events Interest (AEI) during the safety observation period; Frequency of Treatment-Emergent Adverse Event (TEAEs) during the safety observation period; Severity of TEAEs during the safety observation period; Achievement of Complete Response (CR) as determined by the investigator
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.